Approval · Notice of Compliance 26041 · 2021
OLIMEL 4.4%: Notice of Compliance 26041
Issued April 19, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26041
- Date
- April 19, 2021
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To sploit the current product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OLIMEL 4.4% | Not yet assigned | — |
| OLIMEL 5.7% | Not yet assigned | — |
| OLIMEL 7.6% | Not yet assigned | — |
Medicinal ingredients
- AMINO ACIDS 4.4 PER
- DEXTROSE 14 PER
- LIPID 4 PER
- AMINO ACIDS 5.7 PER
- DEXTROSE 11 PER
- AMINO ACIDS 7.6 PER
- DEXTROSE 7.3 PER
- LIPID 3.5 PER